Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.